Home › Researcher directory › M. Balti

M. Balti

Affiliation : Military Hospital of Tunis

• 7Publications (affiliation in Tunisia)
• 12Total publications
• 4Citations
• 1h-index

OpenAlex

Research profile

M. Balti has 7 indexed publications (2019–2026). Their work appears mainly in “Annals of Oncology”, “International Journal of Gynecological Cancer” and “HemaSphere”. 2 of these publications date from the last three years of activity. Their work is co-authored with at least 12 researchers.

Is this you? Get your research seen

Create your free DzCademia profile and add your articles: they will show up more easily on Google and in AI assistants like ChatGPT, so more people can read and cite your work.

Create my free profile Add my publications

Research areas

• Breast Cancer Treatment Studies
• Cancer survivorship and care
• Lymphoma Diagnosis and Treatment
• Reproductive Biology and Fertility
• Breast Lesions and Carcinomas

Publications (7)

• 96eP Frailty and malnutrition as prognostic factors in advanced endometrial cancer: A real-world study from Tunisia
  2026 · ESMO Open
• 2840P Therapeutic education: A catalyst for relieving vomiting, nausea, anxiety, and depression in cancer patients
  2025 · Annals of Oncology
• EPV011/#170 Adjuvant chemotherapy-induced amenorrhea in luminal breast cancer patients: a strong prognostic factor in Tunisian premenopausal women
  2021 · International Journal of Gynecological Cancer
• EPV012/#171 Endocrine therapy-induced alopecia in patients with breast cancer in Tunisia
  2021 · International Journal of Gynecological Cancer
• 196P Menopausal symptoms in premenopausal patients with luminal early breast cancer developing chemotherapy-induced amenorrhea
  2020 · Annals of Oncology
• PF313 NEW TREATMENT FOR DOUBLE/TRIPLE HIT LYMPHOMA WITH DOSE INTENSE PROTOCOL: RITUXIMAB,DOXORUBICIN,ETOPOSIDE,PREDNISOLONE/GEMCITABINE+OXALIPLATIN SHAWING BETTER SURVIVAL RATE
  2019 · HemaSphere
• PS1091 TREATMENT OF ACTIVATED B‐CELL LYMPHOMA WITH RITUXIMAB,DOXORUBICIN,ETOPOSIDE,PREDNISOLONE/IFOSFAMIDE+CISPLATIN PLUS LENALIDOMIDE (R‐ACEP/ICL), CONFERS LONG PROGRESSION FREE AND OVERALL SURVIVAL RATES
  2019 · HemaSphere

Publication venues

• Annals of Oncology × 2
• International Journal of Gynecological Cancer × 2
• HemaSphere × 2
• ESMO Open × 1

Publications per year

• 20261
• 20251
• 20212
• 20201
• 20192

Collaborations

Partner institutions : Hospital Fatuma Bourguiba Monastir · Hopital Universitaire Habib Bourguiba

Co-authors

• S. Fendri
• Aref Zribi
• S. Fendri Ben Chelbia
• I Mejri
• Abderrazek Haddaoui
• Nooshin Mansouri
• A. Haddoui
• Jihene Braham Ayari
• Ramzi Arfaoui
• Ichrak Ben Abdallah
• Sonia Ben Nasr
• L. Dhouibi

Bibliographic data from OpenAlex (open database).